Recommendations for Screening, Risk Stratification, and Targeted Treatment for Diabetic Kidney Disease in the UAE

Abstract

Background

Diabetes remains the leading cause of diabetic kidney disease (DKD) and end-stage renal disease (ESRD), posing a significant health care burden both globally and in the United Arab Emirates. The coexistence of DKD and cardiovascular risk factors increases morbidity and mortality, necessitating the need for an integrated, evidence-based approach in management.

Methods

In response, a panel of endocrinologists and nephrologists from the United Arab Emirates collaborated to develop regional consensus recommendations focusing on the local clinical needs.

Results

This article focuses on DKD stage 1 to 4, providing practical guidance on screening, diagnosis, referral, glycemic control, and risk factor management to help delay DKD progression and reduce complications. Given the complexity of DKD, additional recommendations covering advanced stages, dialysis, and transplantation will be presented as a forthcoming part of this consensus.

Conclusion

These recommendations support a proactive and comprehensive approach to improve renal–metabolic outcomes and address the escalating burden of DKD in the United Arab Emirates.

Keywords

chronic kidney disease - diabetes mellitus - diabetic kidney disease - end-stage renal disease - reno-metabolic - type 2 diabetes

Authors' Contributions

A.B. is the principal author for the manuscript. All authors contributed to the drafting and revising of the manuscript. All authors reviewed the final version of the manuscript and take collective responsibility for all of its contents.

Ethical Approval

No prior ethical approval is needed for a review-type article.

Data Availability Statement

All data, views, and recommendations generated for this initiative are included in this article and its supplementary material files. All primary literature is cited in its bibliography.

Publikationsverlauf

Artikel online veröffentlicht:
22. Januar 2026

• References

• 1 Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008; 51 (05) 714-725 . Accessed December 9, 2024 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292427/
• 2 Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017; 12 (12) 2032-2045
• 3 Levey AS, Coresh J, Balk E. et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139 (02) 137-147
• 4 Pálsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21 (03) 273-280
• 5 Buyadaa O, Magliano DJ, Salim A, Koye DN, Shaw JE. Risk of rapid kidney function decline, all-cause mortality, and major cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes. Diabetes Care 2020; 43 (01) 122-129
• 6 Gao Z, Zhu Y, Sun X. et al. Establishment and validation of the cut-off values of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio for diabetic kidney disease: A multi-center, prospective cohort study. Front Endocrinol (Lausanne) 2022; 13: 1064665
• 7 Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol 2017; 12 (08) 1366-1373
• 8 Al Awadi F, Hassanein M, Hussain HY, Mohammed H, Ibrahim G, Suliman E. Prevalence of diabetes and associated health risk factors among adults in Dubai, United Arab Emirates: Results from Dubai Household Survey 2019. Dubai Diabetes Endocrinol J 2020; 26 (04) 164-173
• 9 International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation; 2021. . Available at: https://diabetesatlas.org/data/ . Accessed January 3, 2025
• 10 Alalawi F, Ahmed M, AlNour H, Noralla M, Alhadari A. Epidemiology of end-stage renal disease in Dubai: Single-center data. Saudi J Kidney Dis Transpl 2017; 28 (05) 1119-1125
• 11 Arman Rabbani S, Belagodu Sridhar S, Gm Rao P. et al. Prevalence and associations of moderately increased albuminuria in patients with type 2 diabetes in United Arab Emirates. Diabetes Metab Syndr 2020; 14 (06) 1865-1870
• 12 Almadani AK, Ahmed W, Al Obaidli AAK, Holt SG. Gender, age and nationality differences in chronic kidney disease prevalence in the Emirate of Abu Dhabi, UAE. Nephrology (Carlton) 2024; 29 (05) 288-296
• 13 Al-Ghamdi SMG, Bieber B, AlRukhaimi M. et al; GCC-DOPPS Study Group. Diabetes prevalence, treatment, control, and outcomes among hemodialysis patients in the Gulf Cooperation Council countries. Kidney Int Rep 2022; 7 (05) 1093-1102
• 14 Bashier A, Farghaly M, Alali JY. et al. Real-world evaluation of demographics, treatment pattern, and economic burden of heart failure and kidney disease in type 2 diabetes mellitus patient population in Dubai, United Arab Emirates. Dubai Diabetes Endocrinol J 2023; 29 (01) 42-54
• 15 Stevens PE, Ahmed SB, Carrero JJ. et al; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105 (4S): S117-S314 . Accessed December 10, 2024 at: https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext
• 16 Hassanein M, Sabbour H, Al Awadi F. et al. Cardiometabolic guidelines: Cardiovascular risk assessment and management in patients with dysglycemia. Dubai Diabetes Endocrinol J 2023; 29: 67-88 . Karger Publishers. Accessed December 9, 2024 at: https://karger.com/dde/article/29/2/67/854055/Cardiometabolic-Guidelines-Cardiovascular-Risk
• 17 Bansal N, Hyre Anderson A, Yang W. et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2015; 26 (04) 946-956 . Accessed December 9, 2024 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378105/
• 18 Yeo SC, Wang H, Ang YG, Lim CK, Ooi XY. Cost-effectiveness of screening for chronic kidney disease in the general adult population: A systematic review. Clin Kidney J 2023; 17 (01) sfad137
• 19 Shlipak MG, Tummalapalli SL, Boulware LE. et al; Conference Participants. The case for early identification and intervention of chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2021; 99 (01) 34-47
• 20 Roy S, Schweiker-Kahn O, Jafry B. et al. Risk factors and comorbidities associated with diabetic kidney disease. J Prim Care Community Health 2021;12:21501327211048556. Accessed November 29, 2024 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516382/
• 21 Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014; 63 (2 Suppl 2): S39-S62
• 22 Friedman AN. Obesity in CKD: A promising path forward. Clin J Am Soc Nephrol 2022; 17 (12) 1817-1819
• 23 Liao D, Ma L, Liu J, Fu P. Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies. PLoS ONE 2019; 14 (02) e0210213
• 24 Yamanouchi M, Furuichi K, Hoshino J. et al. Two-year longitudinal trajectory patterns of albuminuria and subsequent rates of end-stage kidney disease and all-cause death: A nationwide cohort study of biopsy-proven diabetic kidney disease. BMJ Open Diab Res Care 2021; 9: e002241 . Accessed December 10, 2024: https://drc.bmj.com/content/9/1/e002241
• 25 de Boer IH, Rue TC, Cleary PA. et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171 (05) 412-420
• 26 Izzedine H, Escudier B, Rouvier P. et al. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 2013; 24 (09) 2421-2425
• 27 Ghane Shahrbaf F, Assadi F. Drug-induced renal disorders. J Renal Inj Prev 2015; 4 (03) 57-60
• 28 Vanholder R, Annemans L, Brown E. et al; European Kidney Health Alliance. Reducing the costs of chronic kidney disease while delivering quality health care: A call to action. Nat Rev Nephrol 2017; 13 (07) 393-409
• 29 Blunt I, Bardsley M, Strippoli GFM. Pre-dialysis hospital use and late referrals in incident dialysis patients in England: A retrospective cohort study. Nephrol Dial Transplant 2015; 30 (01) 124-129
• 30 Minutolo R, Lapi F, Chiodini P. et al. Risk of ESRD and death in patients with CKD not referred to a nephrologist: A 7-year prospective study. Clin J Am Soc Nephrol 2014; 9 (09) 1586-1593
• 31 Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev 2014; (06) CD007333
• 32 American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44 (Suppl. 01) S73-S84
• 33 Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with CKD: Core Curriculum 2022. Am J Kidney Dis 2022; 79 (05) 728-736 . Accessed November 27, 2024 at: https://linkinghub.elsevier.com/retrieve/pii/S0272638621007629
• 34 King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48 (05) 643-648
• 35 Tran K, Reaven P. Review of the Veteran Affairs diabetes trial: Lessons learned. Rev Endocr Metab Disord 2020; 21 (04) 537-546
• 36 Heller SR. ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care 2009; 32 Suppl 2 (Suppl. 02) S357-S361
• 37 Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: What we learn from subgroup analyses. Diabetes Care 2011; 34 Suppl 2 (Suppl. 02) S107-S108
• 38 Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care 2016; 39 (05) 686-693
• 39 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 02) B21-B29
• 40 de Boer IH, Khunti K, Sadusky T. et al. Diabetes management in chronic kidney disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45 (12) 3075-3090
• 41 Gallagher EJ, Bloomgarden ZT, Le Roith D. Review of hemoglobin A1c in the management of diabetes. Journal of Diabetes 2009; 1: 9-17
• 42 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102 (5S): S1-S127
• 43 Perkovic V, Badve SV, Tuttle KR. Treatment of diabetic kidney disease. UpToDate. Accessed December 9, 2024 at: https://www.uptodate.com/contents/treatment-of-diabetic-kidney-disease
• 44 Triozzi JL, Parker Gregg L, Virani SS, Navaneethan SD. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diab Res Care 2021; 9: e002300 . Accessed November 27, 2024 at: https://drc.bmj.com/lookup/doi/10.1136/bmjdrc-2021-002300
• 45 Agarwal R, Fouque D. The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes. Nephrol Dial Transplant 2023; 38 (02) 253-257 . Accessed December 10, 2024 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923692/
• 46 Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: A systematic review and meta-analysis. Sci Rep 2023; 13 (01) 15922 . Accessed November 27, 2024 at: https://www.nature.com/articles/s41598-023-42989-z
• 47 Georgianos PI, Eleftheriadis T, Liakopoulos V. Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?. Eur J Clin Invest 2023; 53 (02) e13864 . Accessed November 27, 2024 at: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13864
• 48 Herrington WG, Preiss D, Haynes R. et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (06) 749-761
• 49 Herrington WG, Staplin N, Wanner C. et al; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388 (02) 117-127
• 50 Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400 (10365): 1788-1801
• 51 American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47 (Suppl. 01) S219-S230
• 52 Marso SP, Bain SC, Consoli A. et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375 (19) 1834-1844
• 53 Lin Y, Wang TH, Tsai ML. et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol 2023; 22 (01) 60
• 54 Gerstein HC, Colhoun HM, Dagenais GR. et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394 (10193): 121-130
• 55 Perkovic V, Tuttle KR, Rossing P. et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391 (02) 109-121 . Accessed December 10, 2024 at: https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
• 56 Pfeffer MA, Claggett B, Diaz R. et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373 (23) 2247-2257
• 57 Marso SP, Daniels GH, Brown-Frandsen K. et al; LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375 (04) 311-322
• 58 Zhang Y, He D, Zhang W. et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: A network meta-analysis of randomised clinical trials. Drugs 2020; 80 (08) 797-811
• 59 Xie X, Liu Y, Perkovic V. et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016; 67 (05) 728-741
• 60 Vendeville N, Lepage MA, Festa MC, Mavrakanas TA. Clinical outcomes of renin-angiotensin-aldosterone blockade in patients with advanced chronic kidney disease: A systematic review and meta-analysis. Can J Cardiol 2024; 40 (09) 1718-1728 . Accessed November 27, 2024 at: https://onlinecjc.ca/article/S0828-282X(24)00192-2/fulltext
• 61 Sarafidis PA, Sharpe CC, Wood E. et al. Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease. Nephron Clin Pract 2012; 120 (03) c147-c155
• 62 Sarafidis PA, Li S, Chen SC. et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121 (04) 332-340
• 63 Ku E, Inker LA, Tighiouart H, McCulloch C. Initiation of ACE inhibitor and ARBs in patients with advanced CKD: FR-OR44. J Am Soc Nephrol 2023; 34: 40 . Accessed December 11, 2024 at: https://www.researchgate.net/publication/380716999_Initiation_of_ACE_Inhibitor_and_ARBs_in_Patients_with_Advanced_CKD_FR-OR44
• 64 Qiao Y, Shin JI, Chen TK. et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 2020; 180 (05) 718-726
• 65 Fu EL, Evans M, Clase CM. et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: A nationwide study. J Am Soc Nephrol 2021; 32 (02) 424-435
• 66 Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 2000; 160 (05) 685-693
• 67 Chen Q, Liang Y, Yan J. et al. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2023; 195: 110210 . Accessed November 27, 2024 at: https://www.sciencedirect.com/science/article/pii/S0168822722010245
• 68 Lo KB, Rangaswami J, Vaduganathan M. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease. Nephrol Dial Transplant 2023; 38 (04) 845-854
• 69 Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 2022; 179 (13) 3220-3234
• 70 Pitt B, Filippatos G, Agarwal R. et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385 (24) 2252-2263 . Accessed November 27, 2024 at: http://www.nejm.org/doi/10.1056/NEJMoa2110956
• 71 Weir MR, Bakris GL, Pitt B, Agarwal R, Filippatos G, Rossing P. et al. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health Syst Pharm 2023; 80 (24) e505-18
• 72 Agarwal R, Ruilope LM, Ruiz-Hurtado G. et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens 2023; 41 (02) 295-302
• 73 Sarafidis P, Agarwal R, Pitt B. et al; FIDELIO-DKD and FIGARO-DKD Investigators. Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: A FIDELITY subgroup analysis. Clin J Am Soc Nephrol 2023; 18 (05) 602-612
• 74 Bakris GL, Agarwal R, Anker SD. et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383 (23) 2219-2229
• 75 Agarwal R, Filippatos G, Pitt B. et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 2022; 43 (06) 474-484
• 76 Green JB, Mottl AK, Bakris G. et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 2023; 38 (04) 894-903
• 77 Singh AK, Farag YMK, Zheng Z, Bakris GL. Clinical trial designs of emerging therapies for diabetic kidney disease (DKD). Postgrad Med 2024; 136 (06) 585-593
• 78 Neuen BL, Heerspink HJL, Vart P. et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149 (06) 450-462
• 79 Sarafidis PA, Persu A, Agarwal R. et al. Hypertension in dialysis patients: A consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). J Hypertens 2017; 35 (04) 657-676
• 80 Zac-Varghese S, Mark P, Bain S. et al. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: Abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024. BMC Nephrol 2024; 25 (01) 216
• 81 Almahmeed W, Alabadla Z, Al Awadi F. et al. Improving therapeutic adherence and reducing therapeutic inertia in the management of people with cardiometabolic diseases: A call-to-action from the Middle East. Adv Ther 2025; 42 (03) 1340-1359
• 82 Faggiano A, Gualeni A, Barbieri L. et al. Therapeutic inertia in dyslipidemia management for secondary cardiovascular prevention: Results from the Italian ITACARE-P Network. J Clin Med 2025; 14 (02) 493 . Accessed October 20, 2025 at: https://www.mdpi.com/2077-0383/14/2/493
• 83 NICE. Type 2 diabetes in adults: Management. Accessed August 1, 2025 at: https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493
• 84 Hirano T, Satoh N, Kodera R. et al. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort. J Diabetes Investig 2022; 13 (04) 657-667
• 85 KDIGO. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International Supplements. 2013. Accessed December 10, 2024 at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2013-Lipids-Guideline-English.pdf
• 86 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk | European Heart Journal | Oxford Academic [Internet]. Accessed December 10, 2024 at: https://academic.oup.com/eurheartj/article/41/1/111/5556353
• 87 Chu CD, Lamprea-Montealegre JA, Estrella MM. Too many for too few: Finding appropriate nephrology referrals for patients with CKD that optimize outcomes. Am J Kidney Dis 2022; 79 (03) 330-332 . Accessed December 10, 2024 at: https://www.ajkd.org/article/S0272-6386(21)00994-X/fulltext